Impact of MS disease-modifying therapies on antibody and T cell responses following COVID-19 vaccination

被引：0
|
作者：
Sabatino, J. [1 ]
Rowles, W. [1 ]
Mittl, K. [1 ]
Mcpolin, K. [1 ]
Rajan, J. [2 ]
Zamecnik, C. [1 ]
Zhao, C. [1 ]
Dandekar, R. [1 ]
Alvarenga, B. [1 ]
Loudermilk, R. [1 ]
Gerungan, C. [1 ]
Spencer, C. [1 ]
Sagan, S. [1 ]
Augusto, D. [1 ]
Alexander, J. [1 ]
Ho, B. [1 ]
Hollenbach, J. [1 ]
Hollenbach, J. [1 ]
Zamvil, S. [1 ]
Bove, R. [1 ]
机构：
[1] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P979
引用
收藏
页码：795 / 795
页数：1
相关论文
共 50 条
  • [31] Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
    Messina, Nicole L.
    Sperotto, Mariana G.
    Puga, Marco A. M.
    da Silva, Patricia V.
    de Oliveira, Roberto D.
    Moore, Cecilia L.
    Pittet, Laure F.
    Jamieson, Tenaya
    Dalcolmo, Margareth
    dos Santos, Glauce
    Jardim, Bruno
    Lacerda, Marcus V. G.
    Curtis, Nigel
    Croda, Julio
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
    Etemadifar, Masoud
    Sami, Ramin
    Salari, Mehri
    Sedaghat, Nahad
    Sigari, Amirhossein Akhavan
    Aghababaei, Ali
    Najafi, Mohammadreza
    Tehrani, Donya Sheibani
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [33] COVID-19 and multiple sclerosis - prevalence and the impact of disease modifying therapies
    Kieseier, B.
    Rajbhandari, R.
    Altincatal, A.
    Kim, M.
    Berdofe, A.
    Radhakrishnan, M.
    Jung, E.
    Sandrock, A.
    De Moor, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 102 - 103
  • [34] Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
    Golshani, Maryam
    Hrdy, Jiri
    VACCINES, 2022, 10 (02)
  • [35] Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
    Jihad Inshasi
    Raed Alroughani
    Abdullah Al-Asmi
    Jaber Alkhaboury
    Abdullah Alsalti
    Amir Boshra
    Beatriz Canibano
    Dirk Deleu
    Samar Farouk Ahmed
    Ahmed Shatila
    Mona Thakre
    Neurology and Therapy, 2021, 10 : 539 - 555
  • [36] Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
    Inshasi, Jihad
    Alroughani, Raed
    Al-Asmi, Abdullah
    Alkhaboury, Jaber
    Alsalti, Abdullah
    Boshra, Amir
    Canibano, Beatriz
    Deleu, Dirk
    Ahmed, Samar Farouk
    Shatila, Ahmed
    Thakre, Mona
    NEUROLOGY AND THERAPY, 2021, 10 (02) : 539 - 555
  • [37] HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
    Zhang, Eva
    Bond, Katherine
    Nguyen, Oanh
    Kedzierski, Lukasz
    Allen, Lilith F.
    Kedzierka, Katherine
    Christensen, Britt
    GASTROENTEROLOGY, 2022, 162 (07) : S1004 - S1004
  • [38] T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapies
    Wolf, A. S.
    Ravussin, A.
    Konig, M.
    Overas, M. H.
    Solum, G.
    Kjonstad, I. F.
    Chopra, A.
    Holmoy, T.
    Harbo, H. F.
    Syversen, S. W.
    Jorgensen, K. K.
    Hogestol, E. A.
    Vaage, J. T.
    Celius, E. G.
    Lund-Johansen, F.
    Munthe, L. A.
    Nygaard, G. O.
    Mjaaland, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 49 - 49
  • [39] Patient and healthcare professional perspectives of immune dynamics and ms disease-modifying therapies mode of action throughout COVID-19 pandemic
    Burtchell, J.
    Clemmons, D.
    Clemmons, J.
    Graves, J.
    Sweeney, M.
    Kramer, J.
    Ziehn, M.
    Brown, B.
    Weiss, J.
    Obeidat, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 64 - 64
  • [40] Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
    Baba, Cavid
    Ozcelik, Sinem
    Kaya, Ergi
    Samedzada, Ulvi
    Ozdogar, Asiye Tuba
    Cevik, Sumeyye
    Dogan, Yavuz
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
12345